Premium
Possible association between Budd‐Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
Author(s) -
Kurt Mevlüt,
Shorbagi Ali,
Altundag Kadri,
Elkiran Tamer,
Güllü Ibrahim,
Kansu Emin
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20432
Subject(s) - gemtuzumab ozogamicin , medicine , hepatic veno occlusive disease , complication , calicheamicin , refractory (planetary science) , leukemia , gastroenterology , budd–chiari syndrome , salvage therapy , cd33 , chemotherapy , surgery , myeloid leukemia , disease , hematopoietic stem cell transplantation , inferior vena cava , genetics , astrobiology , cd34 , biology , physics , stem cell
Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment. A patient who developed Budd‐Chiari Syndrome with hepatic vein thrombosis following treatment with GO is presented. This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin. Am. J. Hematol. 80:213–215, 2005. © 2005 Wiley‐Liss, Inc.